FTC Eyes Evolving Pay-For-Delay Drug Deals

Law360, New York (September 1, 2011, 7:20 PM EDT) -- The Federal Trade Commission indicated Wednesday that it would take a hard-line approach to pay-for-delay deals in which brand-name drugmakers promise not to introduce their own generic treatments in exchange for competitors delaying entry to the market.

Facing numerous, if largely unsuccessful, challenges to traditional pay-for-delay settlements from the FTC, brand-name pharmaceutical companies are increasingly making deals to stall their authorized generics instead, according to an agency report on authorized generics

The FTC — which has run into problems convincing the judiciary to block litigation settlements...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.